Data Sets

You will find an overview of available data sets from the REPROGRAM project on this page.

If you are interested in using data, please fill out the contact form and mention the number of the dataset you require. A committee will monthly come together to process all requests. If your request is granted, the Data Acces Agreement will be sent you you for a signature, after which transfer of the data can be arranged.

Nr. Data type
1 In vivo data on atherosclerosis-induced epigenetic changes in myeloid (precursor) cells by feeding atherosclerotic LDLR-/- mice a high fat diet.
2 In vivo data on myocardial infarction-induced epigenetic changes in myeloid (precursor) cells.
3 In vivo data on long-lasting changes in innate immune system activation by competitive adoptive transfer of bone marrow harvested from the induced atherosclerosis model.
4 In vivo data on long-lasting changes in training of hematopoietic stem cells by competitive adoptive transfer of bone marrow harvested from the induced atherosclerosis model.
5 In vivo data on long-lasting changes in innate immune system activation by competitive adoptive transfer of bone marrow harvested from the induced myocardial infarction model.
6 In vivo data on long-lasting changes in training of hematopoietic stem cells by competitive adoptive transfer of bone marrow harvested from the induced myocardial infarction model.
7 In vitro screening data of epigenetic modulators for their capacity to reprogram histones and prevent atherogenic risk factor/myocardial infarction -induced histone modifications in immune cells.
8 In vivo data on in vitro identified epigenetic modulators with respect to their effect on immune cell function and phenotype as well as histone modification marks, in relation to their impact on atherosclerotic lesion burden and stage.
9 In vitro data on phenotype characterization of risk factor induced pro-atherogenesis in human innate immune cells and its progenitors from healthy control subjects.
10 In vitro data on the major activating histone modifications upon risk factor induced pro-atherogenesis in human innate immune cells and its progenitors from healthy control subjects using chromatin immunoprecipitation (ChIP) sequencing assays.
11 In vitro data on the transcriptome of human innate immune cells and its progenitors from healthy control subjects upon risk factor induced pro-atherogenesis using RNA sequencing.
12 In vitro metabolome analysis of human innate immune cells and its progenitors from healthy control subjects upon risk factor induced pro-atherogenesis using mass spectrometry.
13 In vitro data on selective compounds targeting epigenetics or cellular metabolism are able to prevent the pro-atherogenic switch in the healthy donor monocytes.
14 In vitro data on bone marrow precursor (hematopoietic stem cells) activation from healthy control subjects assessing lineage differentiation, inflammatory markers and proliferative capacity after exposure to pro-atherogenic substances.
15 In vitro data on trained circulating monocytes isolated from patients with familial hypercholesterolemia using flow cytometry, stimulation assays with TLR ligands, trans-endothelial migration, and analysis of the epigenome, transcriptome and metabolome
16 In vitro data on trained circulating monocytes isolated from patients with isolated elevated levels of lp(a) using flow cytometry, stimulation assays with TLR ligands, trans-endothelial migration, and analysis of the epigenome, transcriptome and metabolome
17 In vitro data on trained circulating monocytes isolated from patients with isolated low HDL cholesterol levels using flow cytometry, stimulation assays with TLR ligands, trans-endothelial migration, and analysis of the epigenome, transcriptome
18 In vitro data on trained circulating monocytes isolated from patients with excessive smoking behaviour using flow cytometry, stimulation assays with TLR ligands, trans-endothelial migration, and analysis of the epigenome, transcriptome and metabolome*
19 In vitro data on trained circulating monocytes isolated from patients with premature atherosclerosis using flow cytometry, stimulation assays with TLR ligands,
20 In vitro data on trained circulating monocytes isolated from patients after an acute cardiovascular event is using flow cytometry,
21 In vitro data on trained monocytes isolated from healthy subjects using flow cytometry, stimulation assays with TLR ligands, trans-endothelial migration, and analysis of the epigenome, transcriptome and metabolome
22 In vitro data on healthy donor monocytes that are exposed to pooled serum of the selected patient groups in presence / absence of specific inhibitors.
23 In vitro data on the lineage differentiation, inflammatory markers and proliferative capacity of hematopoietic stem cells from patients with atherogenic risk factors or post-myocardial infarction.
24 In vitro data on the lineage differentiation, inflammatory markers and proliferative capacity of hematopoietic stem cells from healthy controls.
25 Clinical Study 1+2 (Acronym SIMPEL): Clinical data on epigenetic changes in the promoter region of inflammatory cytokines in patients with familial hypercholesterolemia compared to control subjects and the effect of statin treatment on these epigenetic changes.
26 Clinical Study 1+2 (Acronym SIMPEL): Clinical data on cytokine release in response to stimulation with TLR agonists and ex vivo characterization of monocytes.
27 Clinical Study 1+2 (Acronym VISTA): Clinical 18F-FDG data target-to-background ratio (TBR) following 12 weeks of PCSK-9 inhibition in patients with familial hypercholesterolemia.
28 Clinical Study 1+2 (Acronym VISTA): Clinical 18F-FDG PET activity data in arterial wall and hematopoietic organs (i.e. bone marrow) and circulating immune cell phenotype in patients with familial hypercholesterolemia.
29 Clinical Study 1 (Acronym ISA): Clinical data on trans endothelial migration capability and subtyping of monocytes in patients with renal impairment.
30 Clinical Study 1 (Acronym ISA II): Clinical data on trans endothelial migration capability, subtyping of monocytes in patients with elevated levels of lipoprotein(a).
31 Clinical Study 1 (Acronym ISA II): Clinical data on trans endothelial migration capability, subtyping of monocytes in patients with acute coronary syndrome.
32 Clinical Study 1 (Acronym Anitschkow): Clinical FDG-PET/CT data on the effect of PCSK9 inhibition on arterial wall inflammation.
33 Clinical Study 1 (Acronym Anitschkow): Clinical FDG-PET/CT data on the effect of of PCSK9 inhibition on (elevated) Lp(a).
34 Clinical Study 1 (Acronym TANGO): Clinical data of CER-001 treatment on carotid Mean Vessel Wall Area (MVWA) as compared to placebo using 3T magnetic resonance imaging (3T-MRI) in patients with genetically defined familial primary hypoalphalipoproteinemia and receiving background optimized lipid therapy.
35 Clinical Study 1 (Acronym FLAME-CKD): Clinical data on change in PET/CT target-to-background ratio (TBR) in patients with chronic kidney disease before and after statin therapy.
36 Clinical Study 1 (Acronym CABG): Clinical phenotypic and epigenetic “trained immunity” characteristics of hematopoietic stem and progenitor cells in patients with established and premature atherosclerosis.
37 Clinical Study 1 (Acronym INFLAME): Clinical PET/CT data from patients with acute coronary syndrome.
38 Clinical Study 1 (Acronym VIPER): Clinical PET/CT data from subjects at risk for atherosclerotic disease.
39 Gene score of prevalent SNPs in enzymes contributing to epigenetic modulation in humans.
40 Clinical assessment of predictive value of critical enzymes of epigenetic reprogramming on cardiovascular risk in the general population.
41 Ex vivo data on the reversibility of epigenetic remodeling by lowering LDL-c in relation to inflammatory activation.
42 Ex vivo data on monocyte phenotyping combined with epigenome/transcriptome analysis in patients with genetically elevated LDL cholesterol who underwent statin-induced LDL cholesterol lowering treatment.
43 Clinical study 4: Effect of short-chain fatty acid Butyrate to prevent trained immunity. (study ongoing)
44 Clinical study 4: Effect of short-chain fatty acid Butyrate to prevent trained immunity. (study ongoing)
45 Clinical study 3: Clinical data from a proof-of-concept study in patients at increased cardiovascular risk to evaluate whether epigenetic marks and inflammatory activation can be reversed, using multi-level PET/CT (spleen/bone-marrow/arterial wall) (study to be initiated).
46 Clinical study 3: Ex vivo data on monocyte phenotyping combined with epigenome/transcriptome analysis from a proof-of-concept study in patients at increased cardiovascular risk to evaluate whether epigenetic marks and inflammatory activation can be reversed (study to be initiated).
47 Ex vivo data on nanoparticle delivery of promising treatment candidates by rHDL packaging.
48 In vitro data on the relation between chronic inflammatory disease-associated DAMPs and histone modification in human innate immune cells.
49 In vitro data on genome-wide methylome analysis (DNA methylation and hydroxymethylation) for the assessment of the epigenetic landscape at the level of major activating histone modifications.
50 In vitro data on chromatin immunoprecipitation (ChIP)-sequencing assays for the assessment of the epigenetic landscape at the level of major activating histone modifications.
51 Clinical Study 5 (Acronym ISA): Clinical data on phenotype, function and epigenome of monocytes harvested from rheumatoid arthritis patients, with active disease.
52 Clinical Study 5 (Acronym ISA): Clinical data on phenotype, function and epigenome of monocytes harvested from rheumatoid arthritis patients, with remissive disease.
53 Clinical Study 5 (Acronym (Spondyl)Arthritis): Clinical FDG-PET data for the assessment of inflammatory activity of the arterial wall and bone marrow in patients with active rheumatoid arthritis.
54 Clinical Study 5 (Acronym (Spondyl)Arthritis): Clinical FDG-PET data for the assessment of inflammatory activity of the arterial wall and bone marrow in patients with remissive rheumatoid arthritis.
55 Clinical Study 5 (Acronym ISA): Clinical data on phenotype, function and epigenome of monocytes harvested from healthy control subjects
56 Clinical Study 5 (Acronym (VIPER): Clinical FDG-PET data for the assessment of inflammatory activity of the arterial wall in healthy control subjects.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.